Parkview Ortho Hospital today was the site of the first Two-Level Mobi-C® cervical disc replacement.
This recently FDA approved procedure, performed by Ortho NorthEast surgeon Gregory Hoffman, M.D., is the first and only cervical disc in the U.S. approved to treat more than one level of the cervical spine.
Parkview Ortho Hospital was one of a select group to participate in the investigational device exemption trial. During this trial period, success rates using the two-level cervical disc replacement showed a success rate of 70% compared to fusion showing results of 37%. Those who received the Two-Level Mobi-C cervical disc replacement during the trial phase returned to work three weeks sooner compared to those who were treated using different forms of fusion performed on the cervical spine.
“As the industry evolves, quality of life is at the forefront of driving innovation in the orthopedic industry,” said Julie Fleck, COO, Parkview Ortho Hospital. “As orthopedic replacement devices change and adapt over time, we’re evaluating which devices will help patients heal more efficiently but also have long-term sustainability. This device shows positive signs in both aspects and we were excited to not only participate in the trial phase, but to also be a part of a select group throughout the country to perform this procedure.”
Mobi-C, a trademark of LDR, is a cobalt chromium alloy and polyethylene, mobile-bearing prosthesis specifically designed as a bone-sparing, cervical intervertebral disc replacement for both one- and two-level indications.